

Supplementary Table 8. Trends in triple combination of antidiabetic agents among insulin users with type 2 diabetes mellitus from 2002 to 2019^a

	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019
Metformin	4,163 (97.59)	4,946 (97.46)	5,765 (97.91)	7,440 (97.8)	10,083 (97.34)	10,854 (97.05)	11,724 (96.96)	11,953 (97.43)	11,566 (98.3)	7,785 (98.68)	6,281 (98.6)	6,651 (98.66)	7,086 (97.19)	10,473 (96.63)	14,015 (96.38)	16,677 (96.2)	18,786 (96.00)	19,926 (96.28)
SU	4,191 (98.24)	4,974 (98.01)	5,770 (98.00)	7,437 (97.77)	10,031 (96.83)	10,727 (95.91)	11,554 (95.56)	11,612 (94.65)	11,152 (94.78)	7,500 (95.07)	6,043 (94.87)	6,389 (94.78)	6,674 (91.54)	9,597 (88.55)	12,592 (86.59)	14,884 (85.86)	16,643 (85.05)	17,557 (84.84)
DPP-4i	-	-	-	-	-	-	20 (0.17)	415 (3.38)	594 (5.05)	1,232 (15.62)	2,739 (43.00)	4,273 (63.39)	5,211 (71.47)	9,262 (85.46)	12,600 (86.65)	14,843 (85.62)	16,669 (85.18)	17,169 (82.96)
SGLT2i	-	-	-	-	-	-	-	-	-	-	-	-	68 (0.93)	272 (2.51)	795 (5.47)	1,459 (8.42)	1,757 (8.98)	2,614 (12.63)
TZD	464 (10.88)	491 (9.67)	490 (8.32)	656 (8.62)	857 (8.27)	680 (6.08)	900 (7.44)	847 (6.90)	656 (5.58)	500 (6.34)	552 (8.67)	681 (10.10)	1,220 (16.73)	1,809 (16.69)	2,538 (17.45)	2,940 (16.96)	3,512 (17.95)	3,593 (17.36)
Meglitimide	78 (1.83)	188 (3.70)	265 (4.50)	498 (6.55)	891 (8.60)	1,331 (11.90)	1,457 (12.05)	1,350 (11.00)	890 (7.56)	401 (5.08)	196 (3.08)	188 (2.79)	182 (2.5)	169 (1.56)	204 (1.40)	193 (1.11)	212 (1.08)	165 (0.8)
AGI	3,902 (91.47)	4,626 (91.15)	5,374 (91.27)	6,790 (89.26)	9,215 (88.96)	9,960 (89.06)	10,618 (87.82)	10,627 (86.62)	10,434 (88.68)	6,242 (79.12)	3,290 (51.65)	2,032 (30.14)	1,423 (19.52)	919 (8.48)	772 (5.31)	700 (4.04)	602 (3.08)	490 (2.37)
GLP-1 RA	-	-	-	-	-	-	-	-	6 (0.05)	7 (0.09)	9 (0.14)	9 (0.13)	9 (0.12)	13 (0.12)	110 (0.76)	312 (1.80)	523 (2.67)	571 (2.76)

Values are presented as number (%).

SU, sulfonyleurea; DPP-4i, dipeptidyl peptidase-4 inhibitor; SGLT2i, sodium glucose cotransporter 2 inhibitor; TZD, thiazolidinedione; AGI, alpha glucosidase inhibitor; GLP-1 RA, glucagon-like peptide-1 receptor agonist.

^aEach drug in the triple combination is listed separately.